Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766508 | 0.98 | MAPT (0.38) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17138740 | 0.93 | KDM4E (0.36) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL9410053 | 0.91 | MAPT (0.36) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL1810152 | 0.91 | MAPT (0.36) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL15958834 | 0.89 | CCR2 (0.43) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL12116735 | 0.89 | CCR2 (0.43) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL12116414 | 0.89 | CCR2 (0.43) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL15958833 | 0.89 | CCR2 (0.43) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL17138494 | 0.89 | CCR2 (0.40) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL7618478 | 0.89 | CCR2 (0.43) | MAPTCCR2ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| CN-101454310-B | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI | 2013-07-17 | — | — | CN | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2021337-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2021337-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-101454310-A | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| EP-2021337-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007127726-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127726-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | MAPT 4692/4885CCR2 3902/4885ALDH1A1 51/4885 |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | MAPT 2878/4885CCR2 2815/4885ALDH1A1 1031/4885 |
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, SLC9A1 | MAPT 4238/4885CCR2 2064/4885ALDH1A1 1373/4885 |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | MAPT 4430/4885CCR2 3268/4885ALDH1A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.